Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Biomarkers 2014

Shannon Stott's Biography



Shannon Stott, Assistant Professor, Massachusetts General Hospital & Harvard Medical School

Shannon Stott, Ph.D., is an Assistant Professor in the Department of Medicine at Harvard Medical School and an Assistant in Genetics at the Massachusetts General Hospital Center for Cancer Research. Her laboratory is comprised of bioengineers, physicists and chemists focused on translating technological advances to relevant applications in clinical medicine. Specifically, Shannon is interested in using microfluidics and imaging technologies to create tools that increase understanding of cancer biology and of the metastatic process. In collaboration with the Toner, Haber and Maheswaran laboratories, Shannon has developed microfluidic devices that can isolate extraordinary rare circulating tumor cells (CTCs) from the blood of cancer patients. Her research also includes novel microfluidic devices for extracellular vesicle isolation and molecular characterization with a goal of earlier cancer detection.

Shannon Stott Image

Microfluidic Isolation of Microvesicles from Serum in Glioblastoma

Tuesday, 25 March 2014 at 16:00

Add to Calendar ▼2014-03-25 16:00:002014-03-25 17:00:00Europe/LondonMicrofluidic Isolation of Microvesicles from Serum in GlioblastomaCirculating Biomarkers 2014 in Boston, Massachusetts, USABoston, Massachusetts, USASELECTBIOenquiries@selectbiosciences.com

Microvesicles (MVs) released from cancer cells into the bloodstream contain genetic information about the primary tumor.  These MVs have the potential to be used to guide treatment in glioblastoma patients, but can be challenging to reliably assay due to the heterogeneous population of MVs released from normal cells.  We have taken a microfluidic approach to isolate these tumor derived MVs from human serum, using affinity based capture. Specifically, a microfluidic chaotic mixer is used to direct the MVs to the antibody coated surface of the device. This approach increases our sensitivity of detection of oncogenic mutations, while being cost effective.  Our MV capture and subsequent RNA analysis was validated using tumor MVs from a glioblastoma cell line spiked into healthy human serum. Our data demonstrates that tumor-derived MVs can be selectively captured from serum, providing a  less invasive method to obtain genetic information about the patient’s tumor.


Add to Calendar ▼2014-03-24 00:00:002014-03-25 00:00:00Europe/LondonCirculating Biomarkers 2014Circulating Biomarkers 2014 in Boston, Massachusetts, USABoston, Massachusetts, USASELECTBIOenquiries@selectbiosciences.com